Rupatadine

Drug Profile

Rupatadine

Alternative Names: Alergoliber; Rupafin; Rupatadine fumarate; TK-041; UR 12592

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Uriach
  • Developer Pediapharm; Teikoku Seiyaku; Uriach
  • Class Antiallergics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis; Urticaria
  • Phase III Pruritus
  • Discontinued Atopic dermatitis; Dermatitis

Most Recent Events

  • 25 Jan 2017 Launched for Perennial allergic rhinitis, Seasonal allergic rhinitis and Urticaria (In adolescents, In children, In adults) in Canada (PO, Tablet, Liquid)
  • 31 Jul 2016 Teikoku Seiyaku completes a phase III trial in Perennial allergic rhinitis in Japan (PO) (JapicCTI-152952)
  • 21 Jul 2016 Registered for Perennial allergic rhinitis (In adolescents, In children, In adults) ), Seasonal allergic rhinitis (In adolescents, In adults, In children) and Urticaria (In adolescents, In adults, In children) in Canada (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top